Searched for
MANKIND PHARMA NET PROFIT
Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- KSIIDC pays Rs 143 crore dividend to Karnataka govt; FY25 profit at Rs 188 crore: MB PatilKarnataka State Industrial and Infrastructure Development Corporation (KSIIDC) has presented a dividend exceeding Rs 143 crore to the state...
- Cochin Shipyard shares fall 3% amid buzz around OFS at 8% discountCochin Shipyard shares dipped Monday following reports of a potential government Offer for Sale (OFS) at a discount. The government, aiming...
- Tata Capital shares slip 3% after stock rallies 17% in one week to lifetime high. What’s ahead?Tata Capital shares saw a dip on Monday following a significant rally that propelled them to an all-time high last week. Despite a recent s...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Leader's Premium: The math behind Jio Platforms' priceJio Platforms' upcoming IPO is priced at a premium, reflecting its market leadership and advanced 4G/5G network. Despite smaller revenues t...
- L’Oréal adds Innovist to cart; HealthQuad's new fundHappy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...
- Growth over scale: NSE is priced at a discount to BSENSE's upcoming IPO is set for a discount compared to its peer BSE. This valuation reflects slower growth in NSE's core business. BSE, howev...
- Despite West Asia crisis, net direct tax mopup grows 15% to Rs 5.2 lakh croreIndia's direct tax collections have seen a significant rise of over 14 percent. This growth is driven by strong advance tax payments from c...
- Dhan parent Raise Securities posts Rs 905 crore revenue, profit down 20% in FY26The company had reported net operating income of Rs 795 crore and a profit after tax of Rs 408 crore in FY25. The rating agency attributed ...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
Load More
